NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
Clinical Trials
10 trialsNCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT02725606 2017-08-18
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
Jiangsu T-Mab Biopharma Co.,Ltd
Phase 1 Unknown
NCT03246009 2017-08-11
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Phase 1 Completed
NCT02700360 2016-03-15
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
Enzychem Lifesciences Corporation
Phase 1 Completed
NCT02532712 2016-01-27
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
Enzychem Lifesciences Corporation
Phase 1 Completed
NCT01919710 2015-06-03
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Tianjin SinoBiotech Ltd.
Phase 1 Completed
NCT00520325 2012-09-05
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn